Mindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing
Toronto, Ontario–(Newsfile Corp. – January 6, 2021) – Mindset Pharma Inc. (CSE: MSET) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that certain compounds belonging to its third […]
